A Phase 2, Double-Blind, 12-Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 2 to 11 Years With Symptomatic Nonerosive Gastroesophageal Reflux Disease
Latest Information Update: 18 Nov 2024
At a glance
- Drugs Dexlansoprazole (Primary)
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- Sponsors Takeda; Takeda Development Centre Europe
Most Recent Events
- 13 Nov 2024 Planned End Date changed from 20 Jan 2025 to 31 Oct 2027.
- 13 Nov 2024 Planned primary completion date changed from 20 Jan 2025 to 31 Oct 2027.
- 14 Apr 2024 This study has been completed in Lithuania, according to European Clinical Trials Database record.